Novavax Inc (NVAX)

[mick]

NO LIKE DIS STUFF <> $NVAX <> raised doubts about its ability to remain in business, flagging uncertainties around its revenue and funding crunch.


Novovax – which has its COVID-19 vaccine as the only marketed product after 35 years in business – has raised doubts about its ability to remain in business, flagging uncertainties around its revenue and funding crunch.

The company said in May it expects 2023 revenue between $1.4 billion and $1.6 billion, of which $800 million was from "locked-in" overseas purchase contracts for the COVID shot that it has committed to ship this year.

(Reporting by Khushi Mandowara in Bengaluru; Editing by Shweta Agarwal)